{"i": ["Bevacizumab", "bevacizumab plus lomustine or bevacizumab", "lomustine cytotoxic chemotherapy", "bevacizumab or lomustine", "bevacizumab plus lomustine", "bevacizumab plus lomustine .", "bevacizumab", "cytotoxic chemotherapy and bevacizumab .", "lomustine and bevacizumab", "Lomustine", "systemic chemotherapy", "bevacizumab - based therapy", "bevacizumab in combination with lomustine , bevacizumab single agent or lomustine", "bevacizumab and lomustine cytotoxic chemotherapy", "bevacizumab plus lomustine and bevacizumab", "bevacizumab plus lomustine , bevacizumab", "cytotoxic chemotherapy", "irinotecan", "lomustine", "DRAQ5", "bevacizumab and lomustine", "bevacizumab plus lomustine combination", "bevacizumab plus irinotecan and bevacizumab", "cytotoxic chemotherapy and radiotherapy ."], "o": ["number of CECs", "CEC count", "CEC changes", "CEC kinetics", "absolute CEC counts", "higher absolute CEC counts", "overall survival .", "CEC values", "endothelial damage", "baseline CEC counts and OS .", "maximum tumour diameter", "CEC numbers", "Maximum enhancing tumour diameter", "still alive", "maximum tumour diameter and CEC numbers", "overall survival ( OS ).", "Overall survival ( OS )", "CEC counts", "absolute CEC numbers and improved overall survival", "overall survival", "corticosteroid use and CEC numbers", "Baseline CEC numbers", "CECs and OS", "absolute CEC number", "corticosteroid use", "CECs", "absolute number of CECs", "maximum diameter of the tumour lesion", "absolute CEC counts and OS", "survival benefit", "CD109 - CECs", "tCEC compartment", "Absolute CEC numbers", "CD109 - positive CECs", "absolute CEC numbers", "OS", "CEC changes and OS ."]}